---
figid: PMC5226473__oncotarget-07-48854-g001
figtitle: 'CDK4/6 inhibition: the late harvest cycle begins'
organisms:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC5226473
filename: oncotarget-07-48854-g001.jpg
figlink: /pmc/articles/PMC5226473/figure/F1/
number: F1
caption: 'A non-canonical function of CDK4/6 that can be exploited for therapeutic
  benefit. Left: In a drug-resistant HER2-positive breast cancer cell, CDK4 phosphorylates
  RB and also interacts with TSC2. CDK4 activity enhances mTOR activity, leading to
  feedback suppression of upstream receptor tyrosine kinases (RTKs). Middle: When
  the cell is treated with a CDK4/6 inhibitor (red arrows), RB phosphorylation declines,
  suppressing cell proliferation. TSC2 phosphorylation also declines, reducing mTOR
  activity and relieving feedback inhibition on RTKs. Right: A CDK4/6 inhibitor- treated
  cell is thus primed to the effect of anti-HER2 therapy (e.g. lapatinib, trastuzumab).
  Combination therapy leads to more potent shutdown of mTOR activity and the combined
  mTOR/RB suppression enhances therapeutic effect. (Modified from Goel et al, Cancer
  Cell 2016 [])'
papertitle: 'CDK4/6 inhibition: the late harvest cycle begins.'
reftext: Shom Goel, et al. Oncotarget. 2016 Aug 2;7(31):48854-48856.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8973101
figid_alias: PMC5226473__F1
figtype: Figure
redirect_from: /figures/PMC5226473__F1
ndex: c0f3ff1e-df13-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5226473__oncotarget-07-48854-g001.html
  '@type': Dataset
  description: 'A non-canonical function of CDK4/6 that can be exploited for therapeutic
    benefit. Left: In a drug-resistant HER2-positive breast cancer cell, CDK4 phosphorylates
    RB and also interacts with TSC2. CDK4 activity enhances mTOR activity, leading
    to feedback suppression of upstream receptor tyrosine kinases (RTKs). Middle:
    When the cell is treated with a CDK4/6 inhibitor (red arrows), RB phosphorylation
    declines, suppressing cell proliferation. TSC2 phosphorylation also declines,
    reducing mTOR activity and relieving feedback inhibition on RTKs. Right: A CDK4/6
    inhibitor- treated cell is thus primed to the effect of anti-HER2 therapy (e.g.
    lapatinib, trastuzumab). Combination therapy leads to more potent shutdown of
    mTOR activity and the combined mTOR/RB suppression enhances therapeutic effect.
    (Modified from Goel et al, Cancer Cell 2016 [])'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Cdk4
  - Erbb2
  - Egfr
  - Erbb3
  - Akt1
  - Tsc2
  - Rheb
  - di
  - Mtor
  - Rps6kb1
  - CDK4
  - ERBB2
  - EGFR
  - ERBB3
  - AKT1
  - AKT2
  - AKT3
  - TSC2
  - RHEB
  - RHEBP1
  - MTOR
  - RPS6KB1
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Akt
  - gig
  - norpA
  - Pka-C1
  - Tor
  - S6k
  - rb
  - cdk4
  - her2
  - egfra
  - her3
  - tsc2
  - rheb
  - rhebl1
  - mtor
---
